RNAi-based drug design: considerations and future directions
Open accessThe DOI matches its Crossref record; 264 of the 264 references it cites were found in a registry or an index.
Abstract
More than 25 years after its discovery, the post-transcriptional gene regulation mechanism termed RNAi is now transforming pharmaceutical development, proved by the recent FDA approval of multiple small interfering RNA (siRNA) drugs that target the liver. Synthetic siRNAs that trigger RNAi have the potential to specifically silence virtually any therapeutic target with unprecedented potency and durability. Bringing this innovative class of medicines to patients, however, has been riddled with substantial challenges, with delivery issues at the forefront. Several classes of siRNA drug are under clinical evaluation, but their utility in treating extrahepatic diseases remains limited, demanding continued innovation. In this Review, we discuss principal considerations and future directions in the design of therapeutic siRNAs, with a particular emphasis on chemistry, the application of informatics, delivery strategies and the importance of careful target selection, which together influence therapeutic success. Since the groundbreaking discovery of RNAi more than 25 years ago, several small interfering RNA (siRNA)-based therapies that target the liver have gained approval. This Review discusses principal considerations in siRNA-based drug development, focusing on the medicinal chemistry of siRNA design, the application of informatics, delivery platforms and future directions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–264 of 264
Shmushkovich, T., Monopoli, K. R., Homsy, D., Leyfer, D., Betancur-Boissel, M., Khvorova, A., & Wolfson, A. D. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky745 · Cited by 71
Self-citationEnhancing siRNA efficacy in vivo with extended nucleic acid backbones
Yamada, K., Hariharan, V. N., Caiazzi, J., Miller, R., Ferguson, C. M., Sapp, E., Fakih, H. H., Tang, Q., Yamada, N., Furgal, R. C., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02336-7 · Cited by 67
Self-citationUniversal Barcoding Predicts In Vivo ApoE-Independent Lipid Nanoparticle Delivery
Sanchez, A. J. D. S., Dobrowolski, C. N., Cristian, A., Echeverri, E. S., Zhao, K., Hatit, M. Z. C., Loughrey, D., Paunovska, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01133 · Cited by 66
Huayamares, S. G., Lokugamage, M. P., Rab, R., Da Silva Sanchez, A. J., Kim, H., Radmand, A., Loughrey, D., Lian, L., Hou, Y., Achyut, B. R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.005 · Cited by 65
O’Reilly, D., Belgrad, J., Ferguson, C. M., Summers, A., Sapp, E., McHugh, C. A., Mathews, E. W., Boudi, A., Buchwald, J. E., Ly, S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.05.006 · Cited by 65
Self-citationNuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin
Didiot, M.-C., Ferguson, C. M., Ly, S., Coles, A. H., Smith, A. O., Bicknell, A. A., Hall, L. M., Sapp, E., Echeverria, D., Pai, A. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.106 · Cited by 64
Self-citationSkin Delivery of siRNA Using Sponge Spicules in Combination with Cationic Flexible Liposomes
Liang, X., Zhang, J., Ou, H., Chen, J., Mitragotri, S., & Chen, M. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.04.003 · Cited by 63
Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1
Davis, S. M., Hariharan, V. N., Lo, A. S., Turanov, A. A., Echeverria, D., Sousa, J., McHugh, N., Biscans, A., Alterman, J. F., Karumanchi, S. A., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.06.009 · Cited by 62
Self-citationGeneration and validation of structurally defined antibody–siRNA conjugates
Nanna, A. R., Kel’in, A. V., Theile, C. S., Pierson, J. M., Voo, Z. X., Garg, A., Nair, J. K., Maier, M. A., Fitzgerald, K. J., & Rader, C. M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa286 · Cited by 60
Tao, W., Davide, J. P., Cai, M., Zhang, G.-J., South, V. J., Matter, A., Ng, B., Zhang, Y., & Sepp-Lorenzino, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.147 · Cited by 56
Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin
Tang, Q., Fakih, H. H., Abideen, M. Z. U., Hildebrand, S. R., Afshari, K., Gross, K. Y., Sousa, J., Maebius, A., Bartholdy, C., Søgaard, P. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42714-4 · Cited by 56
Self-citationEngineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo
Biscans, A., Ly, S., McHugh, N., Cooper, D., & Khvorova, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.041 · Cited by 55
Self-citationConroy, F., Miller, R., Alterman, J. F., Hassler, M. R., Echeverria, D., Godinho, B. M. D. C., Knox, E. G., Sapp, E., Sousa, J., Yamada, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33061-x · Cited by 54
Self-citationAlnylam terminates revusiran program, stock plunges
Garber, K. (2016) · Nature Biotechnology · doi:10.1038/nbt1216-1213 · Cited by 53
Godinho, B. M. D. C., Gilbert, J. W., Haraszti, R. A., Coles, A. H., Biscans, A., Roux, L., Nikan, M., Echeverria, D., Hassler, M., & Khvorova, A. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0690 · Cited by 52
Self-citationAutosomal Dominant Stargardt-Like Macular Dystrophy
Donoso, L. A., Edwards, A. O., Frost, A. T., Vrabec, T. R., Stone, E. M., Hageman, G. S., & Perski, T. (2001) · Survey of Ophthalmology · doi:10.1016/s0039-6257(01)00251-x · Cited by 51
Judge, D. P., Kristen, A. V., Grogan, M., Maurer, M. S., Falk, R. H., Hanna, M., Gillmore, J., Garg, P., Vaishnaw, A. K., Harrop, J., et al. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07023-8 · Cited by 51
Fully 2′‐Deoxy‐2′‐Fluoro Substituted Nucleic Acids Induce RNA Interference in Mammalian Cell Culture
Blidner, R., Hammer, R. P., Lopez, M. J., ROBINSON, S. O., & Monroe, W. T. (2007) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00542.x · Cited by 50
Centyrin ligands for extrahepatic delivery of siRNA
Klein, D., Goldberg, S. D., Theile, C. S., Dambra, R., Haskell, K., Kuhar, E., Lin, T., Parmar, R. G., Manoharan, M., Richter, M. C., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.015 · Cited by 50
N-of-1 Trials in Cancer Drug Development
Gouda, M. A., Buschhorn, L., Schneeweiß, A., Wahida, A., & Subbiah, V. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1377 · Cited by 50
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
Hariharan, V. N., Shin, M., Chang, C., O’Reilly, D., Biscans, A., Yamada, K., Guo, Z., Somasundaran, M., Tang, Q., Monopoli, K. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219523120 · Cited by 49
Self-citationEgli, M., Schlegel, M. K., & Manoharan, M. (2023) · RNA · doi:10.1261/rna.079526.122 · Cited by 46
Dual gene targeted multimeric siRNA for combinatorial gene silencing
Hyeon, L. S., Mok, H., Jo, S., Hong, C. A., & Park, T. G. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.062 · Cited by 44
Ly, S., Echeverria, D., Sousa, J., & Khvorova, A. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.029 · Cited by 43
Self-citationBelgrad, J., Tang, Q., Hildebrand, S. R., Summers, A., Sapp, E., Echeverria, D., O’Reilly, D., Luu, E., Bramato, B. M., Allen, S., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae368 · Cited by 40
Self-citationSchlegel, M. K., Matsuda, S., Brown, C. R., Harp, J. M., Barry, J. D., Berman, D., Castoreno, A. B., Schofield, S., Szeto, J., Manoharan, M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab916 · Cited by 39
Ferguson, C. M., Hildebrand, S., Godinho, B. M. D. C., Buchwald, J., Echeverria, D., Coles, A., Grigorenko, A., Vangjeli, L., Sousa, J., McHugh, N., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13703 · Cited by 37
Self-citationCell Type Impacts Accessibility of mRNA to Silencing by RNA Interference
Ferguson, C. M., Echeverria, D., Hassler, M. R., Ly, S., & Khvorova, A. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.06.006 · Cited by 36
Self-citationGuenther, D. C., Mori, S., Matsuda, S., Gilbert, J. A., Willoughby, J. L. S., Hyde, S., Bisbe, A., Jiang, Y., Agarwal, S., Madaoui, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c01679 · Cited by 36
Multi-organ landscape of therapy-resistant melanoma
Liu, S., Dharanipragada, P., Lomeli, S. H., Wang, Y., Zhang, X., Yang, Z., Lim, R. J., Dumitras, C., Scumpia, P. O., Dubinett, S. M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02304-9 · Cited by 35
RNAi-based modulation of IFN-γ signaling in skin
Tang, Q., Sousa, J., Echeverria, D., Fan, X., Hsueh, Y.-C., Afshari, K., MeHugh, N., Cooper, D. A., Vangjeli, L., Monopoli, K., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.04.019 · Cited by 33
Self-citationMonopoli, K. R., Korkin, D., & Khvorova, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.06.010 · Cited by 31
Self-citationRNAi momentum fizzles as pharma shifts priorities
Schmidt, C. (2011) · Nature Biotechnology · doi:10.1038/nbt0211-93 · Cited by 29
Ng, B., Cash-Mason, T., Wang, Y., Seitzer, J. L., Burchard, J., Brown, D., Dudkin, V., Davide, J. P., Jadhav, V., Sepp‐Lorenzino, L., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.013 · Cited by 29
Mandal, S. D., & Ray, P. S. (2020) · Genomics · doi:10.1016/j.ygeno.2020.12.027 · Cited by 29
Chemical strategies for strand selection in short-interfering RNAs
Varley, A., & Desaulniers, J. (2021) · RSC Advances · doi:10.1039/d0ra07747j · Cited by 28
Ferguson, C. M., Godinho, B. M. D. C., Alterman, J. F., Coles, A. H., Hassler, M., Echeverria, D., Gilbert, J. W., Knox, E. G., Caiazzi, J., Haraszti, R. A., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.152203 · Cited by 27 · cited 4×
“Delivering siRNA therapeutics to the CNS is feasible via direct injection into brain regions or infusion into the cerebrospinal fluid (CSF).”
InfluentialSelf-citationSutherland, J. E., Hettinger, J. L., Chan, A., Gilbert, J., Warner, G. L., & Davis, W. P. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0796 · Cited by 27
Godinho, B. M. D. C., Knox, E. G., Hildebrand, S. R., Gilbert, J. W., Echeverria, D., Kennedy, Z., Haraszti, R. Á., Ferguson, C. M., Coles, A. H., Biscans, A., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.06.005 · Cited by 27
Self-citationDrug giants turn their backs on RNA interference
Ledford, H. K. (2010) · Nature · doi:10.1038/468487a · Cited by 25
Dendritic amphiphilic siRNA: Selective albumin binding, in vivo efficacy, and low toxicity
Fakih, H. H., Tang, Q., Summers, A., Shin, M., Buchwald, J. E., Gagnon, R., Hariharan, V. N., Echeverria, D., Cooper, D., Watts, J. K., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102080 · Cited by 25
Self-citationLigand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing
Brown, J. M., Dahlman, J. E., Neuman, K. K., Prata, C. A. H., Krampert, M., Hadwiger, P., & Vornlocher, H. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0782 · Cited by 24
Maraganore, J. M. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01304-3 · Cited by 24
(2017) · Nature Biotechnology · doi:10.1038/nbt.3971 · Cited by 22
Multispecies-targeting siRNAs for the modulation of JAK1 in the skin
Tang, Q., Gross, K. Y., Fakih, H. H., Jackson, S. O., Abideen, M. Z. U., Monopoli, K. R., Blanchard, C., Bouix‐Peter, C., Portal, T., Harris, J. E., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102117 · Cited by 22
Self-citationJongejan, Y. K., Echeverri, E. S., Dirven, R. J., Paunovska, K., Linthorst, N. A., de Jong, A., Wellershoff, J. C., van der Gouw, K. D., van Vlijmen, B. J. M., Dahlman, J. E., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010643 · Cited by 21
Cheng, S.-Y., Caiazzi, J., Biscans, A., Alterman, J. F., Echeverria, D., McHugh, N., Hassler, M. R., Jolly, S. M., Giguere, D., Cipi, J., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102088 · Cited by 21
Self-citationYamada, K., Hildebrand, S. R., Davis, S. M., Miller, R., Conroy, F., Sapp, E., Caiazzi, J., Alterman, J. F., Roux, L., Echeverria, D., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1126 · Cited by 20
Self-citationMachine learning for small interfering RNAs: a concise review of recent developments
Lee, M. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1226336 · Cited by 20
Gayà, A., Munir, T., Urbano-Ispizúa, Á., Griffin, M., Täubel, J., Bush, J. A., Bhan, I., Borodovsky, A., Wang, Y., Badri, P. S., et al. (2023) · eJHaem · doi:10.1002/jha2.748 · Cited by 18
Senior, M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4157 · Cited by 14
Study and Evaluation of the Potential of Lipid Nanocarriers for Transdermal Delivery of siRNA
Lee, K., Min, D., Choi, Y., Kim, J., Yoon, S., Jang, J., Park, S., Tanaka, M., Cho, Y. W., Koo, H., et al. (2020) · Biotechnology Journal · doi:10.1002/biot.202000079 · Cited by 14
Undruggable KRAS—time to rebrand?
Oncology, T. L. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00091-7 · Cited by 13
Amrite, A. C., Fuentes, E., Marbury, T. C., & Zhang, S. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1320 · Cited by 13
Narykov, O., Johnson, N. T., & Korkin, D. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110045 · Cited by 12
A combinatorial approach for achieving CNS-selective RNAi
Ferguson, C. M., Godinho, B. M. D. C., Echeverria, D., Hassler, M. R., Vangjeli, L., Sousa, J., McHugh, N., Alterman, J. F., Hariharan, V. N., Krishnamurthy, P. M., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae100 · Cited by 12
Self-citationHayden, E. C. (2014) · Nature · doi:10.1038/508443a · Cited by 10
Omics and AI advance biomarker discovery for liver disease
Wu, T. E., Cooper, S. A., & Shah, V. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01853-9 · Cited by 8
Ribosomes clear the way for siRNA targeting
Małecka, E. M., & Woodson, S. A. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0495-4 · Cited by 7
N 6-methyladenosine enhances post-transcriptional gene regulation by microRNAs
Kanoria, S., Rennie, W. A., Carmack, C. S., Lü, J., & Ding, Y. (2022) · Bioinformatics Advances · doi:10.1093/bioadv/vbab046 · Cited by 5
Lipophilic siRNA conjugates yield durable silencing in extrahepatic tissues
(2022) · Nature Biotechnology · doi:10.1038/s41587-022-01335-w · Cited by 5
Promising novel siRNA for the treatment of hypertension
Fernández-Ruíz, I. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00916-9 · Cited by 5
Belgrad, J., Tang, Q., Hildebrand, S. R., Summers, A., Sapp, E., Echeverria, D., O’Reilly, D., Luu, E., Bramato, B. M., Allen, S. E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.19.572404 · Cited by 4
Self-citationNovel Cell type-specific aptamer-siRNA delivery system for HIV-1 therapyPreprint
Zhou, J., Li, H., Li, S. X., ZAIA, J. A., & Rossi, J. M. (2007) · Nature Precedings · doi:10.1038/npre.2007.1299.1 · Cited by 3
Cited by
Small and long non-coding RNAs: Past, present, and future
Chen, L.-L., & Kim, V. N. (2024) · Cell · doi:10.1016/j.cell.2024.10.024 · Cited by 425
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Metadata
- Authors
- Tang, Q., & Khvorova, A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2024-04-03
- Volume
- 23
- Issue
- 5
- Pages
- 341-364
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4393869156
- Cited by
- 282
- References
- 264
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.